Pipeline - Mersana Therapeutics

Mersana’s innovative platforms are a highly efficient product engine that is building a robust discovery pipeline for us and our partners. Our ADCs in preclinical and clinical trials are first-in-class molecules that target multiple tumor types with high unmet medical need and have exhibited improved safety and efficacy compared to ADCs developed using first-generation technology. Our lead asset, XMT-1536, is a first-in-class Dolaflexin ADC in a Phase 1 proof-of-concept clinical trial in patients with tumors likely to express NaPi2b, including ovarian cancer and NSCLC adenocarcinoma. Our next clinical stage ADC, XMT-1592, is expected to enter the clinic in the first half of 2020.

ADC Program	Target	Indication	Platform

Clinical
XMT-1536	NaPi2b	Ovarian Cancer NSCLC Adenocarcinoma	Dolaflexin
Preclinical
XMT-1592	NaPi2b	NSCLC Adenocarcinoma Ovarian Cancer	Dolasynthen
Discovery
To Be Named	B7-H4	Multiple Solid Tumors	Dolaflexin or Dolasynthen
To Be Named	Multiple	Multiple Solid Tumors	Immunosynthen
To Be Named	Multiple	Undisclosed	Dolasynthen
To Be Named	Multiple	Undisclosed	Dolaflexin
Platform Collaborations
Multiple	Multiple	Undisclosed	Dolaflexin
ASN004	5T4	Undisclosed	Dolaflexin

Drug	Indication	Stage
Clinical
XMT-1536	NaPi2b	Ovarian Cancer NSCLC Adenocarcinoma	Dolaflexin	Preclinical
Preclinical
XMT-1592	NaPi2b	NSCLC Adenocarcinoma Ovarian Cancer	Dolasynthen	Discovery
Discovery
To Be Named	B7-H4	Multiple Solid Tumors	Dolaflexin or Dolasynthen	Discovery
To Be Named	Multiple	Multiple Solid Tumors	Immunosynthen	Discovery
To Be Named	Multiple	Undisclosed	Dolasynthen
To Be Named	Multiple	Undisclosed	Dolaflexin
Platform Collaborations
Multiple	Multiple	Undisclosed	Dolaflexin	Discovery
ASN004	5T4	Undisclosed	Dolaflexin	Discovery

ADC Program	Target	Indication	Platform	Phase
XMT-1536	NaPi2b*	Ovarian Cancer NSCLC Adenocarcinoma	Dolaflexin	P1 Proof of Concept
XMT-1592	NaPi2b*	NSCLC Adenocarcinoma Ovarian Cancer	Dolasynthen	Preclinical
To Be Named	B7-H4	Multiple Solid Tumors	Dolaflexin or Dolasynthen	Preclinical
To Be Named	Multiple	Multiple Solid Tumors	Immunosynthen	Discovery
To Be Named	Multiple	Undisclosed	Dolasynthen	Discovery
To Be Named	Multiple	Undisclosed	Dolaflexin	Discovery
Multiple	Multiple	Undisclosed	Dolaflexin	Preclinical
ASN004	5T4	Undisclosed	Dolaflexin	Preclinical

*NaPi2b is broadly expressed in ovarian cancer and NSCLC adenocarcinoma, as well as other malignant tumor types. NaPi2b is a member of the SLC34 family of sodium-dependent phosphate transporters and plays an important role in maintaining phosphate homeostasis.